Skip to content

Measuring the anxiety-reducing effects of Tibetan singing bowls

Preventing effects of the relaxation response induced by a sound-based treatment in human anxiety: physiological, electroencephalographic and psychological outcomes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN53976851
Enrollment
100
Registered
2022-02-07
Start date
2020-06-30
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of anxiety Mental and Behavioural Disorders Anxiety disorder, unspecified

Interventions

Participants will be randomly assigned to either Tibetan singing bowl (TSB), progressive muscle relaxation (PMR) or control waiting list (CWL). The experimental session consists of a 30-min session in

Sponsors

Austral University of Chile
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Over 18 and under 60 years old 2. No regular practice of relaxation techniques 3. Without any pharmacological treatment on course 4. Over 39-40 points on Spielberg´s state anxiety inventory as a measure of state anxiety

Exclusion criteria

Exclusion criteria: 1. Under 18 and over 60 years old 2. Previous experience with relaxing techniques (yoga, tai-chi, meditation, etc) 3. Being under current pharmacotherapy

Design outcomes

Primary

MeasureTime frame
Self-reported anxiety measured with the Spielberger State Anxiety Inventory (SAI) pre-experiment (SAI-1; 24 h before the experimental session) and post-experiment (SAI-2; immediately after the experimental session is over)

Secondary

MeasureTime frame
1. Spectral power of theta, alpha and beta neuroelectric bands measured using Emotiv Epoc Flex gel-based sensors at T1 (baseline), T2 (10 min), T3 (20 min) and T4 (30 min) 2. Heart rate variability (HRV) recorded using a Polar Q10 device at T1 (baseline), T2 (10 min), T3 (20 min) and T4 (30 min) 3. EEG recorded with the Emotiv device at T1 (baseline), T2 (10 min), T3 (20 min) and T4 (30 min)

Countries

Chile

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026